Close

Zogenix (ZGNX) Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Met Primary Objective

September 29, 2017 7:01 AM EDT Send to a Friend
Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login